Paraffin-based 6-gene model predicts outcome in diffuse large B-cell lymphoma patients treated with R-CHOP.

摘要: Diffuse large B-cell lymphoma (DLBCL) is a heterogeneous disease characterized by variable clinical outcomes. Outcome prediction at the time of diagnosis paramount importance. Previously, we constructed 6-gene model for outcome DLBCL patients treated with anthracycline-based chemotherapies. However, standard therapy has evolved into rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone (R-CHOP). Herein, evaluated predictive power paraffin-based in R-CHOP–treated patients. RNA was successfully extracted from 132 formalin-fixed paraffin-embedded (FFPE) specimens. Expression 6 genes comprising measured mortality predictor score calculated each patient. The divided low-risk (below median) high-risk (above subgroups significantly different overall survival (OS; P = .002) progression-free (PFS; .038). also predicted OS PFS when considered as continuous (P .002 .010, respectively) independent IPI .008). These findings demonstrate that prognostic value remains significant era R-CHOP treatment can be applied to routine FFPE tissue initial diagnostic biopsies.